Ind-Swift Limited
Ind-Swift Limited (INDSWFTLTD.NS) Stock Competitors & Peer Comparison
See (INDSWFTLTD.NS) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| INDSWFTLTD.NS | ₹15.76 | +6.13% | 853.6M | 0.30 | ₹52.33 | N/A |
| SUNPHARMA.BO | ₹1,795.65 | +0.04% | 4.3T | 39.46 | ₹45.50 | +0.86% |
| SUNPHARMA.NS | ₹1,793.60 | -0.10% | 4.3T | 39.49 | ₹45.42 | +0.86% |
| DIVISLAB.NS | ₹5,997.50 | -0.28% | 1.6T | 64.34 | ₹93.22 | +0.50% |
| DIVISLAB.BO | ₹5,996.00 | -0.28% | 1.6T | 64.33 | ₹93.20 | +0.50% |
| TORNTPHARM.BO | ₹4,266.40 | -0.70% | 1.4T | 67.45 | ₹63.25 | +0.75% |
| TORNTPHARM.NS | ₹4,265.60 | -0.74% | 1.4T | 63.63 | ₹67.04 | +0.75% |
| DRREDDY.BO | ₹1,281.95 | -1.53% | 1.1T | 18.90 | ₹67.84 | +0.62% |
| DRREDDY.NS | ₹1,281.70 | -1.46% | 1.1T | 18.88 | ₹67.90 | +0.62% |
| LUPIN.NS | ₹2,334.80 | -0.55% | 1.1T | 23.02 | ₹101.42 | +0.51% |
Stock Comparison
INDSWFTLTD.NS vs SUNPHARMA.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, SUNPHARMA.BO has a market cap of 4.3T. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while SUNPHARMA.BO trades at ₹1,795.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas SUNPHARMA.BO's P/E ratio is 39.46. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to SUNPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check SUNPHARMA.BO's competition here
INDSWFTLTD.NS vs SUNPHARMA.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, SUNPHARMA.NS has a market cap of 4.3T. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while SUNPHARMA.NS trades at ₹1,793.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas SUNPHARMA.NS's P/E ratio is 39.49. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to SUNPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check SUNPHARMA.NS's competition here
INDSWFTLTD.NS vs DIVISLAB.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, DIVISLAB.NS has a market cap of 1.6T. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while DIVISLAB.NS trades at ₹5,997.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas DIVISLAB.NS's P/E ratio is 64.34. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to DIVISLAB.NS's ROE of +0.17%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to DIVISLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check DIVISLAB.NS's competition here
INDSWFTLTD.NS vs DIVISLAB.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, DIVISLAB.BO has a market cap of 1.6T. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while DIVISLAB.BO trades at ₹5,996.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas DIVISLAB.BO's P/E ratio is 64.33. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to DIVISLAB.BO's ROE of +0.17%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to DIVISLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check DIVISLAB.BO's competition here
INDSWFTLTD.NS vs TORNTPHARM.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, TORNTPHARM.BO has a market cap of 1.4T. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while TORNTPHARM.BO trades at ₹4,266.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas TORNTPHARM.BO's P/E ratio is 67.45. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to TORNTPHARM.BO's ROE of +0.29%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to TORNTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check TORNTPHARM.BO's competition here
INDSWFTLTD.NS vs TORNTPHARM.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, TORNTPHARM.NS has a market cap of 1.4T. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while TORNTPHARM.NS trades at ₹4,265.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas TORNTPHARM.NS's P/E ratio is 63.63. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to TORNTPHARM.NS's ROE of +0.29%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to TORNTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check TORNTPHARM.NS's competition here
INDSWFTLTD.NS vs DRREDDY.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, DRREDDY.BO has a market cap of 1.1T. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while DRREDDY.BO trades at ₹1,281.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas DRREDDY.BO's P/E ratio is 18.90. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to DRREDDY.BO's ROE of +0.16%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to DRREDDY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check DRREDDY.BO's competition here
INDSWFTLTD.NS vs DRREDDY.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, DRREDDY.NS has a market cap of 1.1T. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while DRREDDY.NS trades at ₹1,281.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas DRREDDY.NS's P/E ratio is 18.88. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to DRREDDY.NS's ROE of +0.16%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to DRREDDY.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check DRREDDY.NS's competition here
INDSWFTLTD.NS vs LUPIN.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, LUPIN.NS has a market cap of 1.1T. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while LUPIN.NS trades at ₹2,334.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas LUPIN.NS's P/E ratio is 23.02. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to LUPIN.NS's ROE of +0.27%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to LUPIN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check LUPIN.NS's competition here
INDSWFTLTD.NS vs LUPIN.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, LUPIN.BO has a market cap of 1.1T. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while LUPIN.BO trades at ₹2,334.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas LUPIN.BO's P/E ratio is 24.74. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to LUPIN.BO's ROE of +0.27%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to LUPIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check LUPIN.BO's competition here
INDSWFTLTD.NS vs ZYDUSLIFE.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, ZYDUSLIFE.NS has a market cap of 902.3B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while ZYDUSLIFE.NS trades at ₹896.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas ZYDUSLIFE.NS's P/E ratio is 18.27. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to ZYDUSLIFE.NS's ROE of +0.20%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to ZYDUSLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check ZYDUSLIFE.NS's competition here
INDSWFTLTD.NS vs ZYDUSLIFE.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, ZYDUSLIFE.BO has a market cap of 902.2B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while ZYDUSLIFE.BO trades at ₹896.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas ZYDUSLIFE.BO's P/E ratio is 18.27. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to ZYDUSLIFE.BO's ROE of +0.20%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to ZYDUSLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check ZYDUSLIFE.BO's competition here
INDSWFTLTD.NS vs MANKIND.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, MANKIND.BO has a market cap of 842.2B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while MANKIND.BO trades at ₹2,040.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas MANKIND.BO's P/E ratio is 47.20. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to MANKIND.BO's ROE of +0.13%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to MANKIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check MANKIND.BO's competition here
INDSWFTLTD.NS vs MANKIND.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, MANKIND.NS has a market cap of 841.6B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while MANKIND.NS trades at ₹2,038.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas MANKIND.NS's P/E ratio is 47.29. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to MANKIND.NS's ROE of +0.13%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to MANKIND.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check MANKIND.NS's competition here
INDSWFTLTD.NS vs AUROPHARMA.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, AUROPHARMA.NS has a market cap of 763.3B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while AUROPHARMA.NS trades at ₹1,314.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas AUROPHARMA.NS's P/E ratio is 21.89. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to AUROPHARMA.NS's ROE of +0.11%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to AUROPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check AUROPHARMA.NS's competition here
INDSWFTLTD.NS vs AUROPHARMA.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, AUROPHARMA.BO has a market cap of 763B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while AUROPHARMA.BO trades at ₹1,313.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas AUROPHARMA.BO's P/E ratio is 22.31. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to AUROPHARMA.BO's ROE of +0.11%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to AUROPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check AUROPHARMA.BO's competition here
INDSWFTLTD.NS vs ALKEM.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, ALKEM.NS has a market cap of 639B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while ALKEM.NS trades at ₹5,344.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas ALKEM.NS's P/E ratio is 26.94. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to ALKEM.NS's ROE of +0.19%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to ALKEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check ALKEM.NS's competition here
INDSWFTLTD.NS vs ALKEM.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, ALKEM.BO has a market cap of 638.9B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while ALKEM.BO trades at ₹5,343.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas ALKEM.BO's P/E ratio is 26.94. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to ALKEM.BO's ROE of +0.19%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to ALKEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check ALKEM.BO's competition here
INDSWFTLTD.NS vs GLENMARK.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, GLENMARK.BO has a market cap of 612.5B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while GLENMARK.BO trades at ₹2,170.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas GLENMARK.BO's P/E ratio is 57.51. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to GLENMARK.BO's ROE of +0.12%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to GLENMARK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check GLENMARK.BO's competition here
INDSWFTLTD.NS vs GLENMARK.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, GLENMARK.NS has a market cap of 612.5B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while GLENMARK.NS trades at ₹2,170.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas GLENMARK.NS's P/E ratio is 57.53. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to GLENMARK.NS's ROE of +0.12%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to GLENMARK.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check GLENMARK.NS's competition here
INDSWFTLTD.NS vs LAURUSLABS.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, LAURUSLABS.BO has a market cap of 544.9B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while LAURUSLABS.BO trades at ₹1,009.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas LAURUSLABS.BO's P/E ratio is 64.78. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to LAURUSLABS.BO's ROE of +0.19%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to LAURUSLABS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check LAURUSLABS.BO's competition here
INDSWFTLTD.NS vs LAURUSLABS.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, LAURUSLABS.NS has a market cap of 544.6B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while LAURUSLABS.NS trades at ₹1,008.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas LAURUSLABS.NS's P/E ratio is 64.75. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to LAURUSLABS.NS's ROE of +0.19%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to LAURUSLABS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check LAURUSLABS.NS's competition here
INDSWFTLTD.NS vs SUVENPHAR.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, SUVENPHAR.NS has a market cap of 412.4B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while SUVENPHAR.NS trades at ₹1,078.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas SUVENPHAR.NS's P/E ratio is 98.90. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to SUVENPHAR.NS's ROE of +0.13%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to SUVENPHAR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check SUVENPHAR.NS's competition here
INDSWFTLTD.NS vs SUVENPHAR.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while SUVENPHAR.BO trades at ₹1,075.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to SUVENPHAR.BO's ROE of +0.09%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to SUVENPHAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check SUVENPHAR.BO's competition here
INDSWFTLTD.NS vs IPCALAB.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, IPCALAB.NS has a market cap of 402.4B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while IPCALAB.NS trades at ₹1,586.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas IPCALAB.NS's P/E ratio is 44.30. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to IPCALAB.NS's ROE of +0.12%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to IPCALAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check IPCALAB.NS's competition here
INDSWFTLTD.NS vs IPCALAB.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, IPCALAB.BO has a market cap of 401.8B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while IPCALAB.BO trades at ₹1,583.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas IPCALAB.BO's P/E ratio is 44.15. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to IPCALAB.BO's ROE of +0.12%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to IPCALAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check IPCALAB.BO's competition here
INDSWFTLTD.NS vs AJANTPHARM.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, AJANTPHARM.BO has a market cap of 352.5B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while AJANTPHARM.BO trades at ₹2,821.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas AJANTPHARM.BO's P/E ratio is 34.79. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to AJANTPHARM.BO's ROE of +0.26%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to AJANTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check AJANTPHARM.BO's competition here
INDSWFTLTD.NS vs AJANTPHARM.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, AJANTPHARM.NS has a market cap of 350.8B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while AJANTPHARM.NS trades at ₹2,807.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas AJANTPHARM.NS's P/E ratio is 34.58. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to AJANTPHARM.NS's ROE of +0.26%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to AJANTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check AJANTPHARM.NS's competition here
INDSWFTLTD.NS vs JBCHEPHARM.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, JBCHEPHARM.BO has a market cap of 330.4B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while JBCHEPHARM.BO trades at ₹2,057.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas JBCHEPHARM.BO's P/E ratio is 43.34. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to JBCHEPHARM.BO's ROE of +0.22%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to JBCHEPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check JBCHEPHARM.BO's competition here
INDSWFTLTD.NS vs JBCHEPHARM.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, JBCHEPHARM.NS has a market cap of 330.2B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while JBCHEPHARM.NS trades at ₹2,056.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas JBCHEPHARM.NS's P/E ratio is 43.26. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to JBCHEPHARM.NS's ROE of +0.22%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to JBCHEPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check JBCHEPHARM.NS's competition here
INDSWFTLTD.NS vs EMCURE.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, EMCURE.NS has a market cap of 313.3B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while EMCURE.NS trades at ₹1,652.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas EMCURE.NS's P/E ratio is 36.01. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to EMCURE.NS's ROE of +0.20%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to EMCURE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check EMCURE.NS's competition here
INDSWFTLTD.NS vs PEL.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while PEL.NS trades at ₹1,124.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to PEL.NS's ROE of +0.02%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to PEL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check PEL.NS's competition here
INDSWFTLTD.NS vs ASTRAZEN.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, ASTRAZEN.BO has a market cap of 198.7B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while ASTRAZEN.BO trades at ₹7,946.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas ASTRAZEN.BO's P/E ratio is 98.35. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to ASTRAZEN.BO's ROE of +0.27%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to ASTRAZEN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check ASTRAZEN.BO's competition here
INDSWFTLTD.NS vs ASTRAZEN.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, ASTRAZEN.NS has a market cap of 198.3B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while ASTRAZEN.NS trades at ₹7,931.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas ASTRAZEN.NS's P/E ratio is 98.18. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to ASTRAZEN.NS's ROE of +0.27%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to ASTRAZEN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check ASTRAZEN.NS's competition here
INDSWFTLTD.NS vs WOCKPHARMA.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, WOCKPHARMA.NS has a market cap of 193.3B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while WOCKPHARMA.NS trades at ₹1,189.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas WOCKPHARMA.NS's P/E ratio is 901.14. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to WOCKPHARMA.NS's ROE of +0.01%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to WOCKPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check WOCKPHARMA.NS's competition here
INDSWFTLTD.NS vs WOCKPHARMA.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, WOCKPHARMA.BO has a market cap of 193.2B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while WOCKPHARMA.BO trades at ₹1,189.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas WOCKPHARMA.BO's P/E ratio is 900.80. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to WOCKPHARMA.BO's ROE of +0.01%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to WOCKPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check WOCKPHARMA.BO's competition here
INDSWFTLTD.NS vs PPLPHARMA.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, PPLPHARMA.BO has a market cap of 189.9B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while PPLPHARMA.BO trades at ₹143.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas PPLPHARMA.BO's P/E ratio is -115.73. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to PPLPHARMA.BO's ROE of -0.02%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to PPLPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check PPLPHARMA.BO's competition here
INDSWFTLTD.NS vs ERIS.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, ERIS.BO has a market cap of 185.9B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while ERIS.BO trades at ₹1,342.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas ERIS.BO's P/E ratio is 42.51. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to ERIS.BO's ROE of +0.14%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to ERIS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check ERIS.BO's competition here
INDSWFTLTD.NS vs ERIS.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, ERIS.NS has a market cap of 185.7B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while ERIS.NS trades at ₹1,340.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas ERIS.NS's P/E ratio is 42.53. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to ERIS.NS's ROE of +0.14%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to ERIS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check ERIS.NS's competition here
INDSWFTLTD.NS vs NATCOPHARM.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, NATCOPHARM.NS has a market cap of 175.3B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while NATCOPHARM.NS trades at ₹978.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas NATCOPHARM.NS's P/E ratio is 11.26. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to NATCOPHARM.NS's ROE of +0.20%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to NATCOPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check NATCOPHARM.NS's competition here
INDSWFTLTD.NS vs NATCOPHARM.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, NATCOPHARM.BO has a market cap of 175.2B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while NATCOPHARM.BO trades at ₹978.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas NATCOPHARM.BO's P/E ratio is 11.39. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to NATCOPHARM.BO's ROE of +0.20%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to NATCOPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check NATCOPHARM.BO's competition here
INDSWFTLTD.NS vs NEULANDLAB.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, NEULANDLAB.BO has a market cap of 154.9B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while NEULANDLAB.BO trades at ₹12,072.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas NEULANDLAB.BO's P/E ratio is 86.21. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to NEULANDLAB.BO's ROE of +0.12%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to NEULANDLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check NEULANDLAB.BO's competition here
INDSWFTLTD.NS vs NEULANDLAB.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, NEULANDLAB.NS has a market cap of 154.8B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while NEULANDLAB.NS trades at ₹12,067.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas NEULANDLAB.NS's P/E ratio is 86.75. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to NEULANDLAB.NS's ROE of +0.12%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to NEULANDLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check NEULANDLAB.NS's competition here
INDSWFTLTD.NS vs GRANULES.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, GRANULES.NS has a market cap of 151.5B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while GRANULES.NS trades at ₹624.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas GRANULES.NS's P/E ratio is 27.72. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to GRANULES.NS's ROE of +0.15%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to GRANULES.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check GRANULES.NS's competition here
INDSWFTLTD.NS vs GRANULES.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, GRANULES.BO has a market cap of 151.2B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while GRANULES.BO trades at ₹623.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas GRANULES.BO's P/E ratio is 27.71. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to GRANULES.BO's ROE of +0.15%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to GRANULES.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check GRANULES.BO's competition here
INDSWFTLTD.NS vs JUBLPHARMA.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, JUBLPHARMA.NS has a market cap of 133.7B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while JUBLPHARMA.NS trades at ₹844.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas JUBLPHARMA.NS's P/E ratio is 30.98. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to JUBLPHARMA.NS's ROE of +0.07%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to JUBLPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check JUBLPHARMA.NS's competition here
INDSWFTLTD.NS vs JUBLPHARMA.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, JUBLPHARMA.BO has a market cap of 133.7B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while JUBLPHARMA.BO trades at ₹844.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas JUBLPHARMA.BO's P/E ratio is 30.99. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to JUBLPHARMA.BO's ROE of +0.07%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to JUBLPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check JUBLPHARMA.BO's competition here
INDSWFTLTD.NS vs GLS.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while GLS.NS trades at ₹1,086.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to GLS.NS's ROE of +0.09%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to GLS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check GLS.NS's competition here
INDSWFTLTD.NS vs GLS.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while GLS.BO trades at ₹1,085.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to GLS.BO's ROE of +0.19%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to GLS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check GLS.BO's competition here
INDSWFTLTD.NS vs APLLTD.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, APLLTD.BO has a market cap of 132.4B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while APLLTD.BO trades at ₹673.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas APLLTD.BO's P/E ratio is 21.00. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to APLLTD.BO's ROE of +0.12%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to APLLTD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check APLLTD.BO's competition here
INDSWFTLTD.NS vs APLLTD.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, APLLTD.NS has a market cap of 132.4B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while APLLTD.NS trades at ₹673.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas APLLTD.NS's P/E ratio is 21.00. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to APLLTD.NS's ROE of +0.12%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to APLLTD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check APLLTD.NS's competition here
INDSWFTLTD.NS vs ALIVUS.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, ALIVUS.NS has a market cap of 120.4B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while ALIVUS.NS trades at ₹980.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas ALIVUS.NS's P/E ratio is 22.18. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to ALIVUS.NS's ROE of +0.19%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to ALIVUS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check ALIVUS.NS's competition here
INDSWFTLTD.NS vs ALIVUS.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, ALIVUS.BO has a market cap of 120.3B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while ALIVUS.BO trades at ₹980.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas ALIVUS.BO's P/E ratio is 22.16. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to ALIVUS.BO's ROE of +0.09%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to ALIVUS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check ALIVUS.BO's competition here
INDSWFTLTD.NS vs CAPLIPOINT.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, CAPLIPOINT.NS has a market cap of 118.5B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while CAPLIPOINT.NS trades at ₹1,558.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas CAPLIPOINT.NS's P/E ratio is 19.34. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to CAPLIPOINT.NS's ROE of +0.21%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to CAPLIPOINT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check CAPLIPOINT.NS's competition here
INDSWFTLTD.NS vs CAPLIPOINT.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, CAPLIPOINT.BO has a market cap of 118.4B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while CAPLIPOINT.BO trades at ₹1,557.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas CAPLIPOINT.BO's P/E ratio is 19.36. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to CAPLIPOINT.BO's ROE of +0.21%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to CAPLIPOINT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check CAPLIPOINT.BO's competition here
INDSWFTLTD.NS vs COHANCE.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, COHANCE.NS has a market cap of 115.8B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while COHANCE.NS trades at ₹302.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas COHANCE.NS's P/E ratio is 59.94. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to COHANCE.NS's ROE of +0.09%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to COHANCE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check COHANCE.NS's competition here
INDSWFTLTD.NS vs COHANCE.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, COHANCE.BO has a market cap of 115.6B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while COHANCE.BO trades at ₹302.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas COHANCE.BO's P/E ratio is 59.83. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to COHANCE.BO's ROE of +0.09%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to COHANCE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check COHANCE.BO's competition here
INDSWFTLTD.NS vs CAPPL.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while CAPPL.BO trades at ₹1,446.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to CAPPL.BO's ROE of +0.10%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to CAPPL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check CAPPL.BO's competition here
INDSWFTLTD.NS vs STAR.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, STAR.NS has a market cap of 86.7B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while STAR.NS trades at ₹940.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas STAR.NS's P/E ratio is 16.95. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to STAR.NS's ROE of +0.20%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to STAR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check STAR.NS's competition here
INDSWFTLTD.NS vs STAR.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, STAR.BO has a market cap of 86.6B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while STAR.BO trades at ₹939.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas STAR.BO's P/E ratio is 16.92. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to STAR.BO's ROE of +0.20%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to STAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check STAR.BO's competition here
INDSWFTLTD.NS vs VIYASH.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, VIYASH.NS has a market cap of 81.8B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while VIYASH.NS trades at ₹187.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas VIYASH.NS's P/E ratio is 72.12. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to VIYASH.NS's ROE of +0.10%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to VIYASH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check VIYASH.NS's competition here
INDSWFTLTD.NS vs PGHL.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, PGHL.NS has a market cap of 80.6B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while PGHL.NS trades at ₹4,857.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas PGHL.NS's P/E ratio is 34.05. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to PGHL.NS's ROE of +0.51%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to PGHL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check PGHL.NS's competition here
INDSWFTLTD.NS vs PGHL.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, PGHL.BO has a market cap of 80.4B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while PGHL.BO trades at ₹4,842.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas PGHL.BO's P/E ratio is 33.92. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to PGHL.BO's ROE of +0.51%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to PGHL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check PGHL.BO's competition here
INDSWFTLTD.NS vs AKUMS.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, AKUMS.NS has a market cap of 72.6B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while AKUMS.NS trades at ₹474.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas AKUMS.NS's P/E ratio is 22.72. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to AKUMS.NS's ROE of +0.11%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to AKUMS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check AKUMS.NS's competition here
INDSWFTLTD.NS vs SHILPAMED.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, SHILPAMED.NS has a market cap of 68.4B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while SHILPAMED.NS trades at ₹349.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas SHILPAMED.NS's P/E ratio is 30.97. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to SHILPAMED.NS's ROE of +0.06%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to SHILPAMED.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check SHILPAMED.NS's competition here
INDSWFTLTD.NS vs AARTIPHARM.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, AARTIPHARM.BO has a market cap of 55.2B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while AARTIPHARM.BO trades at ₹609.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas AARTIPHARM.BO's P/E ratio is 25.84. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to AARTIPHARM.BO's ROE of +0.11%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to AARTIPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check AARTIPHARM.BO's competition here
INDSWFTLTD.NS vs AARTIPHARM.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, AARTIPHARM.NS has a market cap of 55.2B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while AARTIPHARM.NS trades at ₹608.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas AARTIPHARM.NS's P/E ratio is 25.82. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to AARTIPHARM.NS's ROE of +0.11%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to AARTIPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check AARTIPHARM.NS's competition here
INDSWFTLTD.NS vs FDC.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, FDC.BO has a market cap of 52.4B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while FDC.BO trades at ₹321.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas FDC.BO's P/E ratio is 24.17. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to FDC.BO's ROE of +0.09%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to FDC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check FDC.BO's competition here
INDSWFTLTD.NS vs FDC.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, FDC.NS has a market cap of 52.3B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while FDC.NS trades at ₹321.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas FDC.NS's P/E ratio is 24.16. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to FDC.NS's ROE of +0.09%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to FDC.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check FDC.NS's competition here
INDSWFTLTD.NS vs SEQUENT.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while SEQUENT.BO trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to SEQUENT.BO's ROE of +0.10%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to SEQUENT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check SEQUENT.BO's competition here
INDSWFTLTD.NS vs SEQUENT.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while SEQUENT.NS trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to SEQUENT.NS's ROE of +0.06%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to SEQUENT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check SEQUENT.NS's competition here
INDSWFTLTD.NS vs SPARC.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, SPARC.NS has a market cap of 39.2B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while SPARC.NS trades at ₹120.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas SPARC.NS's P/E ratio is -14.64. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to SPARC.NS's ROE of +1.25%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to SPARC.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check SPARC.NS's competition here
INDSWFTLTD.NS vs SPARC.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, SPARC.BO has a market cap of 39.2B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while SPARC.BO trades at ₹120.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas SPARC.BO's P/E ratio is -14.64. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to SPARC.BO's ROE of +1.25%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to SPARC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check SPARC.BO's competition here
INDSWFTLTD.NS vs INNOVACAP.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, INNOVACAP.NS has a market cap of 38.4B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while INNOVACAP.NS trades at ₹671.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas INNOVACAP.NS's P/E ratio is 29.03. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to INNOVACAP.NS's ROE of +0.14%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to INNOVACAP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check INNOVACAP.NS's competition here
INDSWFTLTD.NS vs SHILPAMED.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, SHILPAMED.BO has a market cap of 34.2B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while SHILPAMED.BO trades at ₹349.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas SHILPAMED.BO's P/E ratio is 30.97. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to SHILPAMED.BO's ROE of +0.06%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to SHILPAMED.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check SHILPAMED.BO's competition here
INDSWFTLTD.NS vs RPGLIFE.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, RPGLIFE.NS has a market cap of 30.8B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while RPGLIFE.NS trades at ₹1,864.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas RPGLIFE.NS's P/E ratio is 15.21. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to RPGLIFE.NS's ROE of +0.41%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to RPGLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check RPGLIFE.NS's competition here
INDSWFTLTD.NS vs RPGLIFE.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, RPGLIFE.BO has a market cap of 30.7B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while RPGLIFE.BO trades at ₹1,855.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas RPGLIFE.BO's P/E ratio is 15.15. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to RPGLIFE.BO's ROE of +0.41%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to RPGLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check RPGLIFE.BO's competition here
INDSWFTLTD.NS vs SUVEN.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, SUVEN.NS has a market cap of 30.2B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while SUVEN.NS trades at ₹130.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas SUVEN.NS's P/E ratio is -10.57. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to SUVEN.NS's ROE of -1.58%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to SUVEN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check SUVEN.NS's competition here
INDSWFTLTD.NS vs AARTIDRUGS.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, AARTIDRUGS.NS has a market cap of 30.2B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while AARTIDRUGS.NS trades at ₹330.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas AARTIDRUGS.NS's P/E ratio is 14.96. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to AARTIDRUGS.NS's ROE of +0.15%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to AARTIDRUGS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check AARTIDRUGS.NS's competition here
INDSWFTLTD.NS vs AARTIDRUGS.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, AARTIDRUGS.BO has a market cap of 30.2B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while AARTIDRUGS.BO trades at ₹330.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas AARTIDRUGS.BO's P/E ratio is 14.95. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to AARTIDRUGS.BO's ROE of +0.15%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to AARTIDRUGS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check AARTIDRUGS.BO's competition here
INDSWFTLTD.NS vs SUVEN.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, SUVEN.BO has a market cap of 30.2B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while SUVEN.BO trades at ₹130.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas SUVEN.BO's P/E ratio is -10.56. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to SUVEN.BO's ROE of -1.58%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to SUVEN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check SUVEN.BO's competition here
INDSWFTLTD.NS vs GUFICBIO.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, GUFICBIO.BO has a market cap of 28.2B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while GUFICBIO.BO trades at ₹281.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas GUFICBIO.BO's P/E ratio is 56.42. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to GUFICBIO.BO's ROE of +0.08%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to GUFICBIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check GUFICBIO.BO's competition here
INDSWFTLTD.NS vs GUFICBIO.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, GUFICBIO.NS has a market cap of 28.1B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while GUFICBIO.NS trades at ₹280.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas GUFICBIO.NS's P/E ratio is 56.32. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to GUFICBIO.NS's ROE of +0.08%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to GUFICBIO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check GUFICBIO.NS's competition here
INDSWFTLTD.NS vs GUJTHEM.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, GUJTHEM.NS has a market cap of 27.4B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while GUJTHEM.NS trades at ₹251.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas GUJTHEM.NS's P/E ratio is 57.23. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to GUJTHEM.NS's ROE of +0.19%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to GUJTHEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check GUJTHEM.NS's competition here
INDSWFTLTD.NS vs ORCHPHARMA.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, ORCHPHARMA.BO has a market cap of 25.5B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while ORCHPHARMA.BO trades at ₹503.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas ORCHPHARMA.BO's P/E ratio is 134.25. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to ORCHPHARMA.BO's ROE of +0.00%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to ORCHPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check ORCHPHARMA.BO's competition here
INDSWFTLTD.NS vs ORCHPHARMA.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, ORCHPHARMA.NS has a market cap of 25.5B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while ORCHPHARMA.NS trades at ₹502.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas ORCHPHARMA.NS's P/E ratio is 133.24. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to ORCHPHARMA.NS's ROE of +0.01%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to ORCHPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check ORCHPHARMA.NS's competition here
INDSWFTLTD.NS vs NOVARTIND.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, NOVARTIND.BO has a market cap of 24.2B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while NOVARTIND.BO trades at ₹980.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas NOVARTIND.BO's P/E ratio is 24.91. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to NOVARTIND.BO's ROE of +0.13%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to NOVARTIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check NOVARTIND.BO's competition here
INDSWFTLTD.NS vs BLISSGVS.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, BLISSGVS.BO has a market cap of 23.2B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while BLISSGVS.BO trades at ₹219.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas BLISSGVS.BO's P/E ratio is 21.52. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to BLISSGVS.BO's ROE of +0.10%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to BLISSGVS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check BLISSGVS.BO's competition here
INDSWFTLTD.NS vs BLISSGVS.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, BLISSGVS.NS has a market cap of 23.1B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while BLISSGVS.NS trades at ₹217.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas BLISSGVS.NS's P/E ratio is 21.43. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to BLISSGVS.NS's ROE of +0.10%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to BLISSGVS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check BLISSGVS.NS's competition here
INDSWFTLTD.NS vs IOLCP.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, IOLCP.NS has a market cap of 22.9B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while IOLCP.NS trades at ₹77.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas IOLCP.NS's P/E ratio is 19.73. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to IOLCP.NS's ROE of +0.07%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to IOLCP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check IOLCP.NS's competition here
INDSWFTLTD.NS vs IOLCP.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, IOLCP.BO has a market cap of 22.9B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while IOLCP.BO trades at ₹77.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas IOLCP.BO's P/E ratio is 19.73. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to IOLCP.BO's ROE of +0.07%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to IOLCP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check IOLCP.BO's competition here
INDSWFTLTD.NS vs SOLARA.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, SOLARA.BO has a market cap of 21.3B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while SOLARA.BO trades at ₹442.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas SOLARA.BO's P/E ratio is -92.27. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to SOLARA.BO's ROE of -0.02%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to SOLARA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check SOLARA.BO's competition here
INDSWFTLTD.NS vs SOLARA.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, SOLARA.NS has a market cap of 21.3B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while SOLARA.NS trades at ₹442.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas SOLARA.NS's P/E ratio is -92.42. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to SOLARA.NS's ROE of -0.02%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to SOLARA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check SOLARA.NS's competition here
INDSWFTLTD.NS vs UNICHEMLAB.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, UNICHEMLAB.NS has a market cap of 20B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while UNICHEMLAB.NS trades at ₹284.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas UNICHEMLAB.NS's P/E ratio is 6.80. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to UNICHEMLAB.NS's ROE of +0.12%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to UNICHEMLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check UNICHEMLAB.NS's competition here
INDSWFTLTD.NS vs UNICHEMLAB.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, UNICHEMLAB.BO has a market cap of 20B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while UNICHEMLAB.BO trades at ₹283.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas UNICHEMLAB.BO's P/E ratio is 6.79. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to UNICHEMLAB.BO's ROE of +0.12%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to UNICHEMLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check UNICHEMLAB.BO's competition here
INDSWFTLTD.NS vs MOREPENLAB.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, MOREPENLAB.NS has a market cap of 19.8B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while MOREPENLAB.NS trades at ₹36.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas MOREPENLAB.NS's P/E ratio is 20.08. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to MOREPENLAB.NS's ROE of +0.09%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to MOREPENLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check MOREPENLAB.NS's competition here
INDSWFTLTD.NS vs MOREPENLAB.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, MOREPENLAB.BO has a market cap of 19.8B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while MOREPENLAB.BO trades at ₹36.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas MOREPENLAB.BO's P/E ratio is 20.18. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to MOREPENLAB.BO's ROE of +0.09%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to MOREPENLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check MOREPENLAB.BO's competition here
INDSWFTLTD.NS vs ALEMBICLTD.NS Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, ALEMBICLTD.NS has a market cap of 19.4B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while ALEMBICLTD.NS trades at ₹75.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas ALEMBICLTD.NS's P/E ratio is 6.07. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to ALEMBICLTD.NS's ROE of +0.13%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to ALEMBICLTD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check ALEMBICLTD.NS's competition here
INDSWFTLTD.NS vs HIKAL.BO Comparison April 2026
INDSWFTLTD.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.NS stands at 853.6M. In comparison, HIKAL.BO has a market cap of 19.2B. Regarding current trading prices, INDSWFTLTD.NS is priced at ₹15.76, while HIKAL.BO trades at ₹155.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.NS currently has a P/E ratio of 0.30, whereas HIKAL.BO's P/E ratio is 194.88. In terms of profitability, INDSWFTLTD.NS's ROE is -0.45%, compared to HIKAL.BO's ROE of -0.01%. Regarding short-term risk, INDSWFTLTD.NS is more volatile compared to HIKAL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.NS.Check HIKAL.BO's competition here